Amgen price target raised to $210 at BofA/Merrill BofA/Merrill analyst Ying Huang raised Amgen's price target to $210 to reflect the potential impact of proposed tax reform and benefits from a potential repatriation of profits. Huang rates Amgen a Buy
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.